Navigation Links
IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant
Date:11/20/2008

SEATTLE, Nov. 20 /PRNewswire/ -- IDRI (Infectious Disease Research Institute) and Immune Design Corp. announced today that they have entered into an agreement pursuant to which Immune Design Corp. is granted a worldwide exclusive license for the research, development, and commercialization of IDRI's Glycopyranosyl Lipid Adjuvant (GLA) technology for products targeting a number of indications. Focusing on its mission to fight infectious diseases of the developing world, IDRI retains worldwide exclusive rights to GLA for selected diseases affecting predominately the developing world. Under the agreement, IDRI will receive an upfront payment, milestones, and royalty payments as well as shares in Immune Design Corp. Further details on the financial terms were not disclosed.

GLA is specifically engineered to improve a vaccine's interaction with the immune system resulting in an enhanced and directed immune response to the vaccine. "We are excited by the promising preclinical results observed so far with GLA," said Chris Clegg, VP Operations and Technology at Immune Design Corp., a Seattle biotech startup focused on novel immunization strategies. "This innovative adjuvant could drive a major shift in the vaccine field."

"We are using GLA in several of IDRI's priority programs but we also think that it has great potential against diseases outside our scope of action," said Curt Malloy, Senior Vice President, Operations and General Counsel, IDRI. "While we retain the necessary rights to pursue our mission against diseases of poverty, revenues generated by this agreement will assist our research and development activities."

As part of its commitment to provide the not-for-profit sector access to its adjuvant technology, IDRI also retains rights to conduct non-commercial research with GLA and will still have the right to provide it to not-for- profit organizations.

Importantly, Immune Design Corp. has adopted a Global Access Plan which addresses accessibility of GLA-containing products the company would develop for diseases of the developing world.

"Creative business agreements with the private sector are critical for the sustainability of our organization but must not be detrimental to the population we are committed to help. We are pleased to sign an agreement with a company that has put in place a Global Access Plan aimed at applying innovation to tackle diseases that disproportionally affect the world's poorest populations," continued Curt Malloy.

About GLA

GLA is a safe and effective vaccine adjuvant formulation that targets a Toll-Like receptor on human dendritic cells, leading to increased and directed immune responses to a vaccine antigen.

About IDRI

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities, IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most. For more information, go to http://www.idri.org.

About Immune Design Corp.

Immune Design Corp. is Seattle-based vaccine biotech company working to develop innovative vaccine adjuvants and immunization strategies that specifically target dendritic cells, a critical component of the human system in the initiation of antigen specific immune responses. These novel technologies could create an entirely new generation of both prophylactic and therapeutic vaccines.


'/>"/>
SOURCE IDRI (Infectious Disease Research Institute) and Immune Design Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Announces Zook as President
2. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
3. Visualizing asthma-causing immune cells at work
4. Protein-printing technique gives snapshots of immune system defense
5. Peptimmune Presentations at Upcoming Events
6. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
7. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
8. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
9. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
10. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
11. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
Breaking Biology News(10 mins):